Illuccix is FDA Approved to Guide Radioligand Use in Prostate Cancer
Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.
Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
